NOVA EYE MEDICAL LTD (EYE) - Interventional Glaucoma Explained

Send us Fan Mail ASX Investment Opportunity - Nova Eye Medical Ltd (ASX:EYE) One of the biggest surprises in eye health is how often cataracts and glaucoma overlap, and what that means for treatment choices. We’re joined by Tom Spurling, Managing Director of Nova Eye Medical, to unpack interventional glaucoma and the iTrack™ Advance platform, including why “treat earlier” can be a very different patient journey compared with years of glaucoma eye drops and the risks of waiting until the disease is severe. We talk through how iTrack™ Advance can be performed during cataract surgery, the world’s most common operation, and why that channel matters so much for adoption in the US. Tom also explains Nova Eye Medical’s competitive stance in the minimally invasive glaucoma surgery (MIGS) market: a tissue-sparing, implant-free approach versus alternatives that cut tissue, bypass pathways, or leave an implant behind. It’s a clear lens on how clinicians make choices when patient safety, outcomes, and simplicity all compete for attention. On the numbers, we cover FY26 sales growth, expanding gross margins, and what positive EBITDA signals about operating leverage as the business scales. We also look at the market runway in the US, the logic behind FY27 guidance, and where international growth could come from next, including Europe and the longer-term potential of China. If you care about ASX healthcare stocks, medtech commercial execution, or the future of glaucoma treatment, hit subscribe, share the episode with a mate, and leave us a review so more people can find ASX Briefs.